Life sciences

Licence offers:

Personalized monitoring of immunosequencing profiles to advance precision medicine

Personalized monitoring of immunosequencing profiles to advance precision medicine

The University of Antwerp has been developing and refining data mining and machine learning models to process T-cell immunosequencing data. They are now in the process of developing
a toolset and analysis framework for wider use and application within a commercial setting and in search of interested partners. More info

Biomerkers

Biomarkers to support the diagnosis and treatment of human neuropathies

The University of Antwerp has identified biomarkers to support the diagnosis and treatment of CMT neuropathies. These biomarkers can be used to improve clinical diagnosis but also to evaluate therapeutic interventions. More info

RSV

Improved respiratory syncytial virus (RSV) vaccines based on glycan modification of the viral fusion (F) protein

To improve current RSV vaccines, the Laboratory of Microbiology, Parasitology and Hygiene (LMPH) at the university of Antwerp, has set up a strategy by using glycan modifications of the RSV F protein to augment the capacity of the RSV F protein to induce neutralizing antibodies. This approach will be applicable in different types of vaccines, such as DNA vaccines, vector-based vaccines and live-attenuated vaccines. More info
 

Transformed response potentiometric titrations

Transformed response potentiometric titrations

The University of Antwerp has developed a new sensing technique to characterize the interactions between nano- or microparticles and/or (bio)molecules, based on potentiometric titration. The technique can be used to determine affinity constants in bio-molecular, colloidal, pharmaceutical, and many other applications . More info

Technology offer: Mouse model for mutant small heat shock protein mimicking human neuropathy and myopathy

Mouse model for mutant small heat shock protein mimicking human neuropathy and myopathy

The University of Antwerp has developed a mouse model for a mutant small heat shock protein mimicking a human neuropathy and myopathy. Pharmaceutical companies having therapeutic compounds that can be validated can benefit from this mouse model. More info

Life sciences

Novel probiotic Lactobacillus strains for human therapeutic use and personal hygiene

The University of Antwerp isolated Lactobacillus strains and identified a novel L. casei strain carrying a number of advantageous traits indicating potential for probiotic use in human infectious and immunological disease prevention and therapy, and personal hygiene. More info

 

Highly selective and high-affinity autophagy inhibitors for development in oncology


The University of Antwerp has discovered the most potent and selective small molecule autophagy inhibitors reported to date. Compounds target autophagy in a highly specific manner, via inhibition of the cysteine protease Atg4B. Target audience for the technology: pharma/biotech partners that are looking for a development candidate in oncology. More info

 

Lead compounds for dry eye disease and validated dry eye disease rat model


The University of Antwerp has developed a new lead compound and a validated rat model for dry eye disease (DED). Pharmaceutical companies looking for a preclinical candidate for further development in DED related disease can benefit from this established expertise.  More info

 

 

Orally bioavailable inhibitors of fibroblast activation protein (FAP) with development potential in fibrosis, oncology and pathologic tissue remodeling


The University of Antwerp has discovered the most potent and selective small molecule FAP inhibitors reported to date. Compounds have low nanomolar affinities, are orally bioavailable and induce stable, long-term in vivo inhibition. Target audience for the technology: pharma/biotech partners that are looking for a development candidate in oncology and diseases characterized by fibrosis and tissue remodeling. More info

Serine protease inhibitors to treat visceral pain


The University of Antwerp has developed an in vivo proof of concept with serine protease inhibitors in a validated gastrointestinal IBS model for visceral pain. Pharmaceutical companies looking to further test these preclinical candidates for further development in visceral pain-related pathologies can benefit from this established expertise. More info

Smart lab monitoring, powered by artificial intelligence


The University of Antwerp has developed advanced artificial intelligence and machine learning techniques to automatically measure and analyze laboratory performance metrics. This technology enables systematic, unsupervised quality control in biomedical laboratories. More generally it allows the integration of complex process data from a wide variety of connected input sources. More info

 

Visceral pain

Validated gastrointestinal model of visceral pain for preclinical drug testing

The University of Antwerp has developed a validated gastrointestinal models for visceral pain which can be used for in vivo proof of concept of new lead compounds. Pharmaceutical companies looking to test a preclinical candidate for further development in visceral pain-related pathologies can benefit from this established expertise. More info

 

 

Contact

Tom Bosschaerts
Valorisation Manager Life Sciences
Campus Middelheim - Gebouw A
M.A.108
Middelheimlaan 1
2000 Antwerpen
Tel. +32 3 265 91 60
valorisation@uantwerpen.be